Skip to main content
Premium Trial:

Request an Annual Quote

Caris to Offer Signal Genetics' Multiple Myeloma Profiling Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caris Life Sciences will offer Signal Genetics' gene expression profile test for multiple myeloma under an agreement announced today.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US through its Hematology Pathology Services. Signal Genetics' CLIA-certified laboratory in Little Rock, Ark., will analyze the test while Caris will incorporate test results into its summary reports.

Financial and other terms of the deal were not disclosed.

According to New York-based Signal, the MyPRS test offers "the most detailed expression profiling information for multiple myeloma patients available on the market." It analyzes and applies a proprietary algorithm to a defined number of relevant genes to determine a gene expression profile associated with a patient's condition. The profile "allows physicians to gain a predictive view of their patient's prognosis, enabling truly personalized treatment options," Signal said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.